Denmark's financial watchdog said Tuesday the economy is shifting down as the Novo-led pharma boom settles into something closer to the rest of the economy. In a country of 6 million people, Novo's Ozempic and Wegovy had been powering standout growth, but a recent slowdown as obesity drug competition intensifies is starting to register in national data.
The watchdog said shifts at Novo and other drugmakers are now influencing the job market, interest rates, and the krone itself. "Indicators for the pharmaceutical industry point to more moderate production growth in the coming period," it said, adding that "The extraordinary contribution from the pharmaceutical industry will cease in the coming years, and its growth is instead forecast to be roughly the same level as the remaining part of private urban industries." A Bloomberg chart shows the market expects Novo's revenue growth to flatten.
When national growth stories evolve, stay informed with the free Market Briefs newsletter that explains economy, markets and real estate simply
In its autumn report, the Economic Councils, which act as an independent adviser to the government, said that medicine sales will push GDP up 4.2% this year, before overall growth eases to 1.8% in 2027 and 1.3% in 2028. While the finance ministry has repeatedly raised its estimate of fiscal space through 2035 on the back of pharma, the watchdog called that too optimistic and estimated the budget balance at 86 billion kroner ($12.9 billion), about 18 billion kroner below the government's figure. The bottom line: as pharma shifts from sprint to steady jog, Denmark's macro tailwind softens, a signal to reassess exposure to Europe's healthcare leaders and the currency crosswinds tied to them.
As industries reshape national outlooks, get a clear daily take by signing up for the free Market Briefs newsletter
